scholarly journals A guided and personalised treatment in metastatic breast cancer: Optimisation of gene and protein expression in tumor tissue

2018 ◽  
Vol 29 ◽  
pp. viii676
Author(s):  
E. Seront ◽  
S. Lejeune ◽  
B. Petit ◽  
V. Samartzy ◽  
S. Sauvage ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Protein Expression ◽  
Tumor Tissue ◽  
Metastatic Breast ◽  
Gene And Protein Expression ◽  
Personalised Treatment

scholarly journals Viable tumor tissue detection in murine metastatic breast cancer by whole-body MRI and multispectral analysis

2009 ◽  
Vol 62 (6) ◽  
pp. 1423-1430 ◽  
Author(s):  
Kai H. Barck ◽  
Brandon Willis ◽  
Jed Ross ◽  
Dorothy M. French ◽  
Ellen H. Filvaroff ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Tumor Tissue ◽  
Metastatic Breast ◽  
Whole Body ◽  
Whole Body Mri ◽  
Viable Tumor ◽  
Viable Tumor Tissue ◽  
Multispectral Analysis

scholarly journals High protein expression of EZH2 is related to unfavorable outcome to tamoxifen in metastatic breast cancer

2014 ◽  
Vol 25 (11) ◽  
pp. 2185-2190 ◽  
Author(s):  
E.A. Reijm ◽  
A.M. Timmermans ◽  
M.P. Look ◽  
M.E. Meijer-van Gelder ◽  
C.K. Stobbe ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Protein Expression ◽  
Metastatic Breast ◽  
High Protein ◽  
Unfavorable Outcome

HER2 expression and HER2:HER2 dimerization identifies subpopulations of metastatic breast cancer patients with different probabilities of long-term survival following trastuzumab treatment and with different requirements for concomitant chemotherapy

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 10557-10557 ◽  
Author(s):  
M. P. Bates ◽  
C. Desmedt ◽  
J. Sperinde ◽  
W. Huang ◽  
D. Larsimont ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Protein Expression ◽  
Metastatic Breast ◽  
Her2 Overexpression ◽  
Her2 Expression ◽  
Concomitant Chemotherapy ◽  
Term Survival ◽  
Her2 Protein ◽  
Trastuzumab Treatment

10557 Background: Selection of patients for treatment with trastuzumab is currently based on the semi-quantitative measurement of HER2 protein expression (IHC) or gene amplification (FISH). We made quantitative measurements of HER2 expression and homodimerization using a novel assay, eTag, and correlated them with overall survival (OS) and time-to-progression (TTP) following trastuzumab treatment in a cohort of patients with metastatic breast cancer (MBC). We also examined the benefit of concomitant chemotherapy (CT) depending on quantitative HER2 expression. Methods: The Jules Bordet cohort (Brussels, Belgium, N=71) had MBC and prior treatment with at least two CT regimens. Patients received trastuzumab alone or combined with predominantly paclitaxel. Independent medical data review and central confirmation of HER2 overexpression by FISH (N=64) or IHC (N=7) were mandatory. The eTag assay was used to quantitate HER2 protein expression and HER2:HER2 dimers in FFPE specimens. eTag measurements were correlated with OS and TTP using Kaplan-Meier and Cox Proportional Hazards regression analyses. Results: Cox analyses identified three independent correlates of OS and TTP: number of metastatic sites (HROS = 2.4/site, 95%CI 1.5–3.9, p = 0.00019), treatment with trastuzumab only (HROS = 2.8, 95%CI 1.1–7.3, p = 0.036), and HER2 expression level (HROS = 0.24/log10(HER2), 95%CI 0.09–0.7, p = 0.0058). Patients with high HER2 (above median expression) experienced better OS than those with low HER2 (HR 0.24, p = 0.0014). Patients with high HER2 expression did not benefit from added CT (HR = 0.95, 95%CI 0.24–3.8, p = 0.94), while patients with low HER2 expression did (trastuzumab alone HR 4.4, 95% CI 1.3–18, p = 0.018). Similar results were observed for HER2:HER2 dimerization. Conclusions: Within a population of patients selected by FISH or IHC to receive trastuzumab, higher HER2 expression or HER2:HER2 dimerization correlated with better outcomes. Patients with high HER2 expression derived no benefit from concomitant CT, while patients with low HER2 expression benefited significantly from the addition of CT to trastuzumab. No significant financial relationships to disclose.

scholarly journals Comparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer

2017 ◽  
Vol 15 (5) ◽  
pp. 2957-2968 ◽  
Author(s):  
Maren Bredemeier ◽  
Sabine Kasimir-Bauer ◽  
Hans-Christian Kolberg ◽  
Thomas Herold ◽  
Sarah Synoracki ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Tumor Tissue ◽  
Metastatic Breast

scholarly journals ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis

2021 ◽  
Vol 11 ◽  
Author(s):  
Loredana Urso ◽  
Grazia Vernaci ◽  
Jessica Carlet ◽  
Marcello Lo Mele ◽  
Matteo Fassan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Hormone Receptor ◽  
Liquid Biopsy ◽  
Tumor Tissue ◽  
Metastatic Breast ◽  
Metastatic Tumor ◽  
Circulating Tumor Dna ◽  
Hormone Receptor Positive ◽  
Tumor Dna

Endocrine therapy represents the cornerstone of treatment in hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (mBC). The natural course of this disease is marked by endocrine resistance, mainly due to Estrogen Receptor 1 (ESR1) acquired mutations. The aim of this study is to evaluate the concordance between ESR1 status in metastatic tumor specimens and matched circulating tumor DNA (ctDNA). Forty-three patients with HR+, HER2-negative mBC underwent both a metastatic tumor biopsy and a liquid biopsy at the time of disease progression. DNA extracted from formalin fixed paraffin embedded (FFPE) tumor specimens and ctDNA from matched plasma were analyzed by droplet digital (dd)PCR for the main ESR1 mutations (Y537S, Y537C, Y537N, D538G, E380Q). We observed a total mutation rate of 21%. We found six mutations on tissue biopsy: Y537S (1), D538G (2), Y537N (1), E380Q (2). Three patients with no mutations in tumor tissue had mutations detected in ctDNA. The total concordance rate between ESR1 status on tumor tissue and plasma was 91%. Our results confirm the potential role of liquid biopsy as a non-invasive alternative to tissue biopsy for ESR1 mutation assessment in mBC patients.

Sign in / Sign up

Export Citation Format

Share Document